Why Keep Covering PPIs? November 26, 2009
Posted by George Van Antwerp in Healthcare, Managed Care, PBM / Pharmacy.trackback
I’m not a clinician so I’m sure there are some clinical exceptions to this general comment. [For example, look at Aetna's PPI Medicare information.]
But, with Prilosec available OTC (Over The Counter) both as a brand product and as a generic (omeprazole) and now Prevacid will also be available OTC, I wonder why PBMs and plan sponsors don’t stop covering this class of drugs. [See here for CVS Caremark's overview on this.]
BTW – PPIs (or Proton Pump Inhibitors) are generally used for acid reflux and some people can simply use other OTCs such as H2 Antagonists (e.g., Tagamet, Pepcid, Zantac). [Consumers might also read Consumer Reports Best Buy Drugs report on PPIs.]
Traditionally, PPIs represented one of the higher cost drug categories (and also one of the most highly rebated). In CVS Caremark’s BOB (book-of-business), it represented 7.3% of their spend according to their TrendsRx 2009 publication.
Plans have stopped covering NSA (non-sedating antihistamines) once Claritin went OTC. This seems like the next natural category with perhaps some formulary override option for certain medical exceptions.
Comments»
No comments yet — be the first.